Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

Humoral immune mechanisms involved in protective and pathological immunity during COVID-19

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Synergism of TNF- and IFN- Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

[COVID-19 from the Perspective of Haematology and Haemostaseology]

Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn

Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword

Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses

Immune Response to SARS-CoV-2 and Mechanisms of Immunopathological Changes in COVID-19.

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections

The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?

Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art

COVID-19: immunopathogenesis and Immunotherapeutics

Serum Inflammatory Factors Are Positively Correlated with the Production of Specific Antibodies in Coronavirus Disease 2019 Patients

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Clinical and Pathological Investigation of Patients with Severe COVID-19

COVID-19: Imbalanced Cell-Mediated Immune Response Drives to Immunopathology

Targeting Inflammation and Cytokine Storm in COVID-19

Proinflammatory IgG Fc structures in patients with severe COVID-19

Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19

The Protective Mechanism Against COVID-19, Antibody vs Cellular Immunity: An Extensive Review

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection